PubMed Health⌕ Search

Biomedical subjects

J Perriot

Publications and source records attributed to J Perriot.

6 recordsLinked to original sources
PubMed2006

[Provision of smoking cessation therapy].

INTRODUCTION: Smoking cessation therapies help well motivated smokers give up and increase the chance of success. BACKGROUND: Medical, behavioural and cognitive cessation therapies are aimed at relieving the secondary effects of stopping smoking: withdrawal symptoms and the urgent need to smoke. A prolonged follow up helps to prevent relapse. VIEWPOINT: The education of doctors and the development of new drugs should increase the rate of successful withdrawal. CONCLUSION: All doctors, particularly respiratory physicians, should be involved in smoking cessation. The aim of this practical guide is to help them in everyday practice.

Humans↗
PubMed2005

[Maternal and paternal smoking: risk excess to tobacco smoking in pregnant women].

Active and passive smoking is a health risk and its toxicity during pregnancy is well known; nevertheless, in France, nearly 30% of pregnant women smoke. The aim of this study is to describe the toxic effects of smoking during pregnancy by a review of the international literature. At the outcome of this study, it appears that besides the well known effects of smoking on pregnancy, foetal development and state of health of the mother and child, other effects may be encountered such as neuropsychiatric, infections, endocrine, metabolic and cardiorespiratory events. While complementary studies are necessary to define the nature of the relationship between the observed effects and smoking, this study underlines the fact that the reduction of prevalence of smoking in pregnant women is a major health issue.

Fathers↗
PubMed1997

Peculiarities of the GSTM1 0/0 genotype in French heavy smokers with various types of chronic bronchitis.

A homozygous gene deletion of the glutathione S-transferase M1 (GSTM1) locus of genomic DNA from blood spots was studied by the polymerase chain reaction in a group of French heavy smokers (n = 361), which included patients with severe chronic bronchitis (SCB; n = 87), moderate chronic bronchitis (MCB: n = 102) and hard smokers (HS) with no permanent clinical symptoms of chronic bronchitis (n = 172). The GSTM1 0/0 genotype was found in 71.3% and 65.7% of cases in SCB and MCB, respectively, compared with only 47.1% in the control HS group (P = 0.0002). This latter figure (47.1%) is consistent with the average GSTM1 deletion frequency in French Caucasians. Moreover, the results showed a significant difference in the distribution of the GSTM1 0/0 genotype for both the SCB and MCB groups against the control HS group, according to gender (SCB: P = 0.001; MCB: P = 0.005), age (SCB: P = 0.0001; MCB: P = 0.005) and smoking history (SCB: P = 0.0001; MCB: P = 0.005). Thus, individuals homozygous for the GSTM1 gene deletion, especially in the under-41 age group (SCB: P = 0.001; MSB: P = 0.04) with an average smoking history of 16-30 pack-years (SCB: P = 0.002; MSB: P = 0.01) are more prone to chronic lung diseases, such as SCB and MCB, than are GSTM1 +/+ or 0/+ subjects. Population screening of young people for the identification of GSTM1 0/0 subjects, with special emphasis on smoking habits, might be useful (1) for the early detection of individuals at high risk of lung complications caused by environmental toxins and pollutants and (2) in clinical practice, in order to prevent the development of chronic bronchitis, which is a common disease.

Adult↗
PubMed1996

Proportion of the GSTM1 0/0 genotype in some Slavic populations and its correlation with cystic fibrosis and some multifactorial diseases.

A homozygous gene deletion at the glutathione S-transferase M1 (GSTM1) locus of genomic DNA from blood spots was studied by PCR in the group of Slavic populations from the north-western and central-eastern regions of European Russia and in patients with lung cancer (LC), other tumors (OT), endometriosis (E), alcoholic cirrhosis (AC), cystic fibrosis (CF) and chronic bronchitis (CB). The frequencies of the GSTM1 0/0 genotype were 38.8% and 67.5% for both population groups, respectively. The proportion of the GSTM1 gene deletion genotype was estimated as significantly increased in LC (81%), OT (65%), E (81%), AC (77.3%), and in CB (73.6%) patients with symptoms of CB confirmed by X-ray but not in CB patients without X-ray evidence of disease (40.9%). A definite preponderance of GSTM1-0 homozygotes (51.1%) has been registered in CF patients of the pancreatic sufficient group with clear-cut pulmonological manifestations but not in those of the pancreatic insufficient group with predominantly intestinal or mixed clinical symptoms (41.2% and 37.5%, respectively). Earlier clinical manifestations and death before the age of 5 years are typical for GSTM1-deleted CF patients. These data support the notion that GSTM1 deletion should be considered as a convenient genetic marker for the early detection of groups at higher risk of many diseases caused by environmental and genetic factors, where manifestation depends on the lack of detoxification. High levels of GSTM1 0/0 genotypes in E patients favor the substantial contribution of certain environmental toxins in the pathogenesis of this widespread disease.

Adolescent↗